EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real‐World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema ( HAE ): Post‐Marketing Surveillance in Japan

Kumiko Hosono iD, Miyako Hoshino iD

The Journal of Dermatology · 2026-11 · 53 (11) · 1599-1614

DOI: 10.1111/1346-8138.70447 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 21.08.2026. Verfasst von Kumiko Hosono und 1 weiteren Autor:innen. Beteiligte Einrichtung: Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan. Hauptthemen laut MEDLINE: Bradykinin B2 Receptor Antagonists, Angioedemas, Hereditary, Bradykinin. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary angioedema (HAE) is a rare, autosomal dominant, life‐threatening disease characterized by recurrent attacks of swelling of the face, upper airway, gastrointestinal tract, limbs, and/or genitalia. Genetic mutations of the SERPING1 gene encoding the C1‐inhibitor (C1‐INH) plasma protein are associated with HAE‐C1INH. HAE is also observed in patients with normal C1‐INH (HAE‐nC1INH). Icatibant is a selective bradykinin B2 receptor antagonist for treatment of acute attacks of HAE. Here we report safety and effectiveness data from a post‐marketing, open‐label, multicenter observational study of icatibant conducted in Japan ( ClinicalTrials.gov ID: NCT04057131). Patients with HAE in Japan who initiated icatibant between November 2018 and June 2020 were enrolled; surveillance was completed in April 2023. In the Safety Analysis Set ( n = 155), most patients were women ( n = 116, 74.84%) and HAE types included HAE‐C1INH‐Type 1 ( n = 83, 53.55%), HAE‐C1INH‐Type 2 ( n = 9, 5.81%), unclassified HAE‐C1INH ( n = 16, 10.32%), and HAE‐nC1INH ( n = 22, 14.19%). Overall, 19 patients (12.26%) experienced adverse drug reactions (ADRs), most of which were mild in severity ( n = 18, 11.61%). The most common ADRs were general disorders and administration site conditions ( n = 18, 11.61%). No serious ADRs or ADRs of special interest other than hypersensitivity and injection site reaction were reported. In the Effectiveness Analysis Set ( n = 100), 97 patients (97.00%) received 30 mg of icatibant. Among 417 HAE attacks, 234 were treated with icatibant alone and 48 with icatibant plus other. Among attacks treated with icatibant alone, median (interquartile range) time to first symptom relief was 60.0 (30.0–270.0) min, and median time to complete resolution of symptoms was 710.0 (148.5–1440.0) min. In conclusion, in this study of the real‐world use of icatibant, no new safety concerns were reported. Icatibant was effective in providing early symptom relief for HAE attacks across a broad spectrum of patients, including patients with HAE‐nC1INH, who were not included in previous clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bradykinin B2 Receptor AntagonistsAngioedemas, HereditaryBradykininHumansFemaleJapanMaleAdultMiddle AgedProduct Surveillance, PostmarketingTreatment OutcomeAgedComplement C1 Inhibitor ProteinAdolescentYoung AdultChild

Stichwörter der Autor:innen

Japanbradykinin B2 receptor antagonisthereditary angioedemaicatibanton‐demand treatmentreal‐world evidence

Substanzen

icatibantBradykinin B2 Receptor AntagonistsBradykininComplement C1 Inhibitor ProteinSERPING1 protein, human

Autor:innen und Institutionen

  • Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.

ORCID-Profile: Kumiko Hosono, Miyako Hoshino

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Hosono, K., & Hoshino, M. (2026). Real‐World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema ( HAE ): Post‐Marketing Surveillance in Japan. The Journal of Dermatology, 53(11), 1599-1614. https://doi.org/10.1111/1346-8138.70447

Vancouver

Hosono K, Hoshino M. Real‐World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema ( HAE ): Post‐Marketing Surveillance in Japan. The Journal of Dermatology. 2026;53(11):1599-1614. doi:10.1111/1346-8138.70447

BibTeX
@article{Hosono2026,
  author = {Hosono, Kumiko and Hoshino, Miyako},
  title = {Real‐World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema ( HAE ): Post‐Marketing Surveillance in Japan},
  journal = {The Journal of Dermatology},
  year = {2026},
  volume = {53},
  number = {11},
  pages = {1599--1614},
  doi = {10.1111/1346-8138.70447}
}
Kostenlos starten →